Statins and endocrine resistance in breast cancer

Abstract

Most breast cancers are hormone-receptor positive (HR⁺). However, more women eventually die from HR⁺ breast cancer than from either HER2⁺ or triple negative breast cancer. Endocrine therapies continue to be the mainstay of treatment. In 40% of these cases, recurrences in early-stage disease and progression in the metastatic setting are largely a function of the development of endocrine resistance. A multitude of mediators and pathways have been associated with endocrine resistance in breast cancer including the mevalonate pathway, which is integral to cholesterol biosynthesis. The mevalonate pathway and the downstream activation of associated cytoplasmic pathways including PI3K-AKT-mTOR and RAS-MEK-ERK have been known to affect cancer cell proliferation, cell survival, cell invasion, and metastasis. These are important mechanisms leading to the inevitable development of endocrine resistance in HR⁺ breast cancer. Statins are a class of drugs that inhibits HMG-CoA reductase, an enzyme in the mevalonate pathway that plays a central role in cholesterol production. In vitro and in vitro studies suggest that the role of statins in blocking the mevalonate pathway effectively disrupts downstream pathways involved in estrogen receptor expression and cellular processes such as cell survival, proliferation, stress, cell cycle, inhibition of apoptosis, and autophagy. Overcoming these key mechanisms heralds a role for statins in the prevention of endocrine resistance.

Keywords

Statin / HMGCR / endocrine resistance / autophagy / PI3K / mTOR

References

[1] DeSantis CE,Gaudet MM.Breast cancer statistics, 2019..CA Cancer J Clin2019;69:438-51

[2] Patel HK.Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment..Pharmacol Ther2018;186:1-24

[3] Osborne CK.Mechanisms of endocrine resistance in breast cancer..Annu Rev Med2011;62:233-47 PMCID:PMC3656649

[4] Cardoso F,Costa A,Aapro M.4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)..Ann Oncol2018;29:1634-57 PMCID:PMC7360146

[5] Murphy CG.Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies..Endocr Relat Cancer2016;23:R337-52

[6] Mürdter TE,Bacchus-Gerybadze L.Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma..Clin Pharmacol Ther2011;89:708-17

[7] Gutierrez MC,Johnston S.Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase..J Clin Oncol2005;23:2469-76

[8] Lindström LS,Wilking UM.Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression..J Clin Oncol2012;30:2601-8

[9] Schointuch MN,Stine JE.Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer..Gynecol Oncol2014;134:346-55 PMCID:PMC4125536

[10] Wong WW,Minden MD.HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis..Leukemia2002;16:508-19

[11] Graaf MR,van Noorden CJ.Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer..Cancer Treat Rev2004;30:609-41

[12] Kwan ML,Flick ED,Caan B.Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors..Breast Cancer Res Treat.2008;109:573-9 PMCID:PMC3507509

[13] Ahern TP,Tarp M.Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study..J Natl Cancer Inst2011;103:1461-8 PMCID:PMC3186780

[14] Hultsch S,Paavolainen L.Association of tamoxifen resistance and lipid reprogramming in breast cancer..BMC Cancer2018;18:850 PMCID:PMC6109356

[15] Augimeri G,Gelsomino L.Evidence for enhanced exosome production in aromatase inhibitor-resistant breast cancer cells..Int J Mol Sci2020;21:5841 PMCID:PMC7461508

[16] Hendrix A,Pauwels P.Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis..J Natl Cancer Inst2010;102:866-80 PMCID:PMC2886092

[17] Frittoli E,Marighetti P.A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination..J Cell Biol2014;206:307-28 PMCID:PMC4107781

[18] Howe EN,Justice ME.Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth..Nat Commun2020;11:3017 PMCID:PMC7295786

[19] Silva P,Rivas S.Hypoxia promotes Rab5 activation, leading to tumor cell migration, invasion and metastasis..Oncotarget2016;7:29548-62 PMCID:PMC5045416

[20] Jia X,Lei L.Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer..Oncotarget2015;6:8648-62 PMCID:PMC4496173

[21] Campbell RA,Patel NM,Ali S.Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance..J Biol Chem2001;276:9817-24

[22] Miller TW,González-Angulo AM.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer..J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[23] Sokolosky ML,Chappell WH.Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy..Oncotarget2011;2:538-50 PMCID:PMC3248182

[24] Cavazzoni A,Fumarola C.Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones..Cancer Lett2012;323:77-87

[25] Bosco EE,Xu H.The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer..J Clin Invest2007;117:218-28 PMCID:PMC1679964

[26] Maiorano D,Méchali M.MCM proteins and DNA replication..Curr Opin Cell Biol2006;18:130-6

[27] Ibarra A,Méndez J.Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication..Proc Natl Acad Sci U S A2008;105:8956-61 PMCID:PMC2449346

[28] Liang Z,Liu J.Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells..Sci Rep2017;7:41776 PMCID:PMC5288718

[29] Campisi J.Aging, cellular senescence, and cancer..Annu Rev Physiol2013;75:685-705 PMCID:PMC4166529

[30] Davalos AR,Malhotra GK.p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes..J Cell Biol2013;May 13201:613-29 PMCID:PMC3653366

[31] Liu S,Demaria M,Campisi J.Simvastatin suppresses breast cancer cell proliferation induced by senescent cells..Sci Rep2015;5:17895 PMCID:PMC4677323

[32] Musgrove EA.Biological determinants of endocrine resistance in breast cancer..Nat Rev Cancer2009;9:631-43

[33] Debidda M,Zheng Y.Rac1 GTPase regulates cell genomic stability and senescence..J Biol Chem2006;281:38519-28

[34] Mandlekar S,Tan TH.Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells..Cancer Res2000;60:5995-6000

[35] Moriai R.,Moriai M,Watanabe N.Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells..Breast Cancer Res Treat2009;117:261-71

[36] Hall A.Rho GTPases and the actin cytoskeleton..Science1998;279:509-14

[37] Elson CE,Hentosh P.Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer..Proc Soc Exp Biol Med1999;221:294-311

[38] Kusama T,Tatsuta M,Inoue M.Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho..Int J Oncol2006;29:217-23

[39] Liu Y,Zhang H.Fatostatin in combination with tamoxifen induces synergistic inhibition in ER-positive breast cancer..Drug Des Devel Ther2020;14:3535-45 PMCID:PMC7457819

[40] Iizuka-Ohashi M,Sukeno M.Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells..Oncotarget2018;9:19597-612 PMCID:PMC5929411

[41] Rabinowitz JD.Autophagy and metabolism..Science2010;330:1344-8 PMCID:PMC3010857

[42] Samaddar JS,Duplantier J.A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance..Mol Cancer Ther2008;7:2977-87

[43] Liu J,Chen H.The correlation between autophagy and tamoxifen resistance in breast cancer..Int J Clin Exp Pathol2019;12:2066-74 PMCID:PMC6949623

[44] Miettinen TP.Mevalonate pathway regulates cell size homeostasis and proteostasis through autophagy..Cell Rep2015;13:2610-20 PMCID:PMC4709259

[45] Shojaei S,Samiei E.Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes..FEBS J2020;287:1005-34

[46] Misirkic M,Vucicevic L.Inhibition of AMPK-dependent autophagy enhances in vitro antiglioma effect of simvastatin..Pharmacol Res2012;65:111-9

[47] Toepfer N,Parikh A,Yang W.Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription..Cancer Biol Ther2011;12:691-9

[48] Qi W,Liu Y.Simvastatin aggravates impaired autophagic flux in NSC34-hSOD1G93A cells through inhibition of geranylgeranyl pyrophosphate synthesis..Neuroscience2019;409:130-41

[49] Harborg S,Ahern TP,Cronin-Fenton D.Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study..Breast Cancer Res Treat2020;183:153-60 PMCID:PMC7376511

[50] Gu Q,Burt VL.Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012..NCHS Data Brief2014;1771-8

[51] Lazar LD,Coxson PG,Goldman L.Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era..Circulation2011;124:146-53

[52] Bhaskaran K,Forbes H,Leon DA.Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults..Lancet2014;384:755-65 PMCID:PMC4151483